Datasets:
SKT27182
/
NER

Dataset card Viewer Files Community
1
ID
stringlengths
11
11
tags
stringlengths
10
777
text
stringlengths
2
1.5k
dataset_num
int64
1
3
tokens
sequence
ner_tags
sequence
NCT01626079
1:24:chronic_disease,35:42:treatment,46:72:treatment
Tricuspid valve disease requiring surgery or transcatheter intervention
3
[ "Tricuspid", "valve", "disease", "requiring", "surgery", "or", "transcatheter", "intervention" ]
[ 2, 2, 2, 0, 1, 0, 1, 1 ]
NCT01625923
44:75:chronic_disease,,124:140:treatment,142:163:treatment,165:177:treatment,180:194:treatment
Use of medications potentially influencing upper gastrointestinal motility or appetite within one week of the study (e.g., prokinetic drugs, macrolide antibiotics (erythromycin), GLP-1 mimetics)
3
[ "Use", "of", "medications", "potentially", "influencing", "upper", "gastrointestinal", "motility", "or", "appetite", "within", "one", "week", "of", "the", "study", "(", "e.g.", ",", "prokinetic", "drugs", ",", "macrolide", "antibiotics", "(", "erythromycin", ")", ",", "GLP-1", "mimetics", ")" ]
[ 0, 0, 0, 0, 0, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 0 ]
NCT01625234
20:68:treatment,70:93:treatment,99:120:treatment
Patients receiving CYP3A substrates with narrow therapeutic indices, strong CYP3A inhibitors, and strong CYP3A inducers
3
[ "Patients", "receiving", "CYP3A", "substrates", "with", "narrow", "therapeutic", "indices", ",", "strong", "CYP3A", "inhibitors", ",", "and", "strong", "CYP3A", "inducers" ]
[ 0, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 1, 0, 0, 0, 0, 0 ]
NCT01624090
,,67:81:treatment,83:87:treatment,92:102:treatment
Cardiac Function: Left ventricular ejection fraction (EF) >40% by Echocardiogram, MUGA, or cardiac MR
3
[ "Cardiac", "Function", ":", "Left", "ventricular", "ejection", "fraction", "(", "EF", ")", ">", "40", "%", "by", "Echocardiogram", ",", "MUGA", ",", "or", "cardiac", "MR" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 1, 1 ]
NCT01624090
27:39:treatment,41:57:treatment,62:79:treatment,90:100:cancer,,131:140:treatment
Patients must have had no chemotherapy, biologic therapy, or radiation therapy for their malignancy for at least 30 days prior to treatment
3
[ "Patients", "must", "have", "had", "no", "chemotherapy", ",", "biologic", "therapy", ",", "or", "radiation", "therapy", "for", "their", "malignancy", "for", "at", "least", "30", "days", "prior", "to", "treatment" ]
[ 0, 0, 0, 0, 0, 1, 0, 1, 1, 0, 0, 1, 1, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 1 ]
NCT01624090
15:22:cancer,24:34:cancer,38:51:cancer,56:89:cancer
patients with gastric, colorectal or renal cancers and sarcomas metastatic to the thorax
3
[ "patients", "with", "gastric", ",", "colorectal", "or", "renal", "cancers", "and", "sarcomas", "metastatic", "to", "the", "thorax" ]
[ 0, 0, 3, 0, 3, 0, 3, 3, 0, 3, 3, 3, 3, 3 ]
NCT01622868
,21:34:cancer,51:71:treatment,75:98:treatment,102:142:treatment,146:181:treatment,
HER2-overexpressing breast cancer (3+ staining by immunohistochemistry or HER2 gene amplification by fluorescent in situ hybridization [FISH] or silver in situ hybridization [SISH] >= 2.0)
3
[ "HER2-overexpressing", "breast", "cancer", "(", "3+", "staining", "by", "immunohistochemistry", "or", "HER2", "gene", "amplification", "by", "fluorescent", "in", "situ", "hybridization", "[", "FISH", "]", "or", "silver", "in", "situ", "hybridization", "[", "SISH", "]", ">", "=", "2.0", ")" ]
[ 1, 1, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0 ]
NCT01620216
16:37:chronic_disease,39:45:chronic_disease,50:67:treatment
Any history of myocardial infarction, stroke, or revascularization
3
[ "Any", "history", "of", "myocardial", "infarction", ",", "stroke", ",", "or", "revascularization" ]
[ 0, 0, 0, 2, 2, 0, 2, 0, 0, 1 ]
NCT01620216
1:12:treatment,71:81:treatment,,145:157:chronic_disease
hydroxyurea is allowed prior to enrollment and after the start of the study drug for the control of peripheral leukemic blasts in subjects with leukocytosis per physician discretion
3
[ "hydroxyurea", "is", "allowed", "prior", "to", "enrollment", "and", "after", "the", "start", "of", "the", "study", "drug", "for", "the", "control", "of", "peripheral", "leukemic", "blasts", "in", "subjects", "with", "leukocytosis", "per", "physician", "discretion" ]
[ 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0 ]
NCT01619761
1:33:cancer,38:72:cancer,78:97:chronic_disease,108:124:treatment
Small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with progressive disease following standard therapy
3
[ "Small", "lymphocytic", "lymphoma", "(", "SLL", ")", ",", "or", "chronic", "lymphocytic", "leukemia", "(", "CLL", ")", "with", "progressive", "disease", "following", "standard", "therapy" ]
[ 3, 3, 3, 3, 0, 0, 0, 0, 3, 3, 3, 3, 0, 0, 0, 2, 2, 0, 1, 1 ]
NCT01618357
47:54:chronic_disease,56:67:chronic_disease,69:74:chronic_disease,76:83:chronic_disease,85:101:chronic_disease,103:114:chronic_disease,118:150:chronic_disease,154:162:chronic_disease
Clinically significant and uncontrolled major cardiac, respiratory, renal, hepatic, gastrointestinal, hematologic or neurological/psychiatric disease or disorder
3
[ "Clinically", "significant", "and", "uncontrolled", "major", "cardiac", ",", "respiratory", ",", "renal", ",", "hepatic", ",", "gastrointestinal", ",", "hematologic", "or", "neurological/psychiatric", "disease", "or", "disorder" ]
[ 0, 0, 0, 0, 0, 2, 0, 2, 0, 2, 0, 2, 0, 2, 0, 2, 0, 2, 2, 0, 2 ]
NCT01618357
15:23:cancer,28:50:cancer,54:76:cancer
Patients with squamous, or metaplastic carcinomas or sarcomas of the breast
3
[ "Patients", "with", "squamous", ",", "or", "metaplastic", "carcinomas", "or", "sarcomas", "of", "the", "breast" ]
[ 0, 0, 3, 0, 0, 3, 3, 0, 3, 3, 3, 3 ]
NCT01618357
,,,117:124:treatment,126:135:treatment,140:149:treatment
Women of child-bearing potential must also have a negative pregnancy test within 2 weeks prior to start of protocol therapy (radiation and veliparib)
3
[ "Women", "of", "child-bearing", "potential", "must", "also", "have", "a", "negative", "pregnancy", "test", "within", "2", "weeks", "prior", "to", "start", "of", "protocol", "therapy", "(", "radiation", "and", "veliparib", ")" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 1, 0 ]
NCT01617161
1:14:treatment,30:34:treatment,37:48:treatment,50:73:treatment,75:87:treatment,91:108:treatment
Prior surgery (not including TURP), cryosurgery, radiofrequency ablation, chemotherapy or radiation for PCa
3
[ "Prior", "surgery", "(", "not", "including", "TURP", ")", ",", "cryosurgery", ",", "radiofrequency", "ablation", ",", "chemotherapy", "or", "radiation", "for", "PCa" ]
[ 1, 1, 0, 0, 0, 1, 0, 0, 1, 0, 1, 1, 0, 1, 0, 1, 1, 1 ]
NCT01614197
1:14:chronic_disease,16:21:chronic_disease,23:32:chronic_disease,37:56:chronic_disease,67:79:treatment
Active fungal, viral, bacterial, or protozoal infection requiring IV treatment
3
[ "Active", "fungal", ",", "viral", ",", "bacterial", ",", "or", "protozoal", "infection", "requiring", "IV", "treatment" ]
[ 2, 2, 0, 2, 0, 2, 0, 0, 2, 2, 0, 1, 1 ]
NCT01614197
1:15:treatment,54:80:treatment,92:99:treatment,101:129:treatment
Anticoagulants: Patients who are currently receiving therapeutic anticoagulants (including aspirin, low molecular weight heparin, and others) are not eligible
3
[ "Anticoagulants", ":", "Patients", "who", "are", "currently", "receiving", "therapeutic", "anticoagulants", "(", "including", "aspirin", ",", "low", "molecular", "weight", "heparin", ",", "and", "others", ")", "are", "not", "eligible" ]
[ 1, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 1, 0, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0 ]
NCT01614197
1:14:treatment,,69:82:treatment,89:103:treatment,108:155:treatment
Immunotherapy: At least 30 days after the completion of any type of immunotherapy, e.g. tumor vaccines. or chimeric antigen receptor T cell (CART) therapy or tumor vaccines
3
[ "Immunotherapy", ":", "At", "least", "30", "days", "after", "the", "completion", "of", "any", "type", "of", "immunotherapy", ",", "e.g", ".", "tumor", "vaccines", ".", "or", "chimeric", "antigen", "receptor", "T", "cell", "(", "CART", ")", "therapy", "or", "tumor", "vaccines" ]
[ 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 1, 0, 0, 1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0 ]
NCT01608438
149:166:treatment,174:198:treatment,202:218:treatment,220:246:treatment,252:262:treatment
Any metal in head with the exception of dental work or any ferromagnetic metal elsewhere in the body. This applies to all metallic hardware such as cochlear implants, or an Internal Pulse Generator or medication pumps, implanted brain electrodes, and peacemaker
3
[ "Any", "metal", "in", "head", "with", "the", "exception", "of", "dental", "work", "or", "any", "ferromagnetic", "metal", "elsewhere", "in", "the", "body", ".", "This", "applies", "to", "all", "metallic", "hardware", "such", "as", "cochlear", "implants", ",", "or", "an", "Internal", "Pulse", "Generator", "or", "medication", "pumps", ",", "implanted", "brain", "electrodes", ",", "and", "peacemaker" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 1, 1, 1, 0, 1, 1, 0, 1, 1, 1, 0, 0, 1 ]
NCT01604512
25:28:treatment,36:45:treatment,47:60:treatment,62:77:treatment
Any contraindication to MRI (e.g., pacemaker, aneurysm clip, tissue expander)
3
[ "Any", "contraindication", "to", "MRI", "(", "e.g.", ",", "pacemaker", ",", "aneurysm", "clip", ",", "tissue", "expander", ")" ]
[ 0, 0, 0, 1, 0, 0, 0, 1, 0, 1, 1, 0, 1, 1, 0 ]
NCT01600040
45:75:treatment,79:99:treatment,104:119:treatment,131:143:treatment
Have undergone simple, modified radical, or radical abdominal hysterectomy or vaginal hysterectomy and lymphadenectomy by open or laparoscopic assisted technique
3
[ "Have", "undergone", "simple", ",", "modified", "radical", ",", "or", "radical", "abdominal", "hysterectomy", "or", "vaginal", "hysterectomy", "and", "lymphadenectomy", "by", "open", "or", "laparoscopic", "assisted", "technique" ]
[ 0, 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 1, 1, 0, 1, 0, 0, 0, 1, 0, 0 ]
NCT01599559
36:51:chronic_disease,103:126:chronic_disease,128:152:chronic_disease
Evidence of clinically significant cardiac disease at diagnosis, as defined by history of symptomatic ventricular arrhythmias, congestive heart failure
3
[ "Evidence", "of", "clinically", "significant", "cardiac", "disease", "at", "diagnosis", ",", "as", "defined", "by", "history", "of", "symptomatic", "ventricular", "arrhythmias", ",", "congestive", "heart", "failure" ]
[ 0, 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 0, 2, 2, 2 ]
NCT01597518
96:107:treatment,132:149:treatment,153:161:treatment
Subject is currently using, and will continue to use for the next 14 days any of the following medications which are classified as CYP1A2 inhibitors or inducers
3
[ "Subject", "is", "currently", "using", ",", "and", "will", "continue", "to", "use", "for", "the", "next", "14", "days", "any", "of", "the", "following", "medications", "which", "are", "classified", "as", "CYP1A2", "inhibitors", "or", "inducers" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 1, 0, 1 ]
NCT01591356
12:46:chronic_disease,42:45:chronic_disease,87:109:treatment
History of human immunodeficiency virus (HIV) or HIV-positive patients on combination antiretroviral therapy are ineligible
3
[ "History", "of", "human", "immunodeficiency", "virus", "(", "HIV", ")", "or", "HIV-positive", "patients", "on", "combination", "antiretroviral", "therapy", "are", "ineligible" ]
[ 0, 0, 2, 2, 2, 2, 2, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0 ]
NCT01591356
26:55:chronic_disease,57:63:chronic_disease,66:97:chronic_disease,101:124:chronic_disease,,162:171:treatment
Patients with history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within 6 months of the first date of treatment on this study
3
[ "Patients", "with", "history", "of", "cerebrovascular", "accident", "(", "CVA", ",", "stroke", ")", ",", "transient", "ischemic", "attack", "(", "TIA", ")", "or", "subarachnoid", "hemorrhage", "within", "6", "months", "of", "the", "first", "date", "of", "treatment", "on", "this", "study" ]
[ 0, 0, 0, 0, 2, 2, 2, 0, 0, 2, 0, 0, 2, 2, 2, 2, 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0 ]
NCT01589263
5:32:treatment,43:81:treatment,86:89:chronic_disease
Any prior surgical intervention or use of 5-alpha-reductase medical intervention for BPH
3
[ "Any", "prior", "surgical", "intervention", "or", "use", "of", "5-alpha-reductase", "medical", "intervention", "for", "BPH" ]
[ 0, 1, 1, 1, 0, 0, 0, 1, 1, 1, 0, 2 ]
NCT01589263
12:36:chronic_disease,38:59:chronic_disease,61:86:chronic_disease,91:124:chronic_disease,
Episode of unstable angina pectoris, myocardial infarction, transient ischemic attack, or cerebrovascular accident (stroke) within the past 6 months
3
[ "Episode", "of", "unstable", "angina", "pectoris", ",", "myocardial", "infarction", ",", "transient", "ischemic", "attack", ",", "or", "cerebrovascular", "accident", "(", "stroke", ")", "within", "the", "past", "6", "months" ]
[ 0, 0, 2, 2, 2, 0, 2, 2, 0, 2, 2, 2, 0, 0, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0 ]
NCT01584076
13:20:chronic_disease,32:38:chronic_disease,40:69:chronic_disease,71:87:chronic_disease,89:109:chronic_disease,118:138:chronic_disease,160:166:treatment
Presence of cardiac condition, asthma, obstructive pulmonary disease, seizure disorder, urinary incontinence, and/or peptic ulcer disease receiving concurrent NSAIDs
3
[ "Presence", "of", "cardiac", "condition", ",", "asthma", ",", "obstructive", "pulmonary", "disease", ",", "seizure", "disorder", ",", "urinary", "incontinence", ",", "and/or", "peptic", "ulcer", "disease", "receiving", "concurrent", "NSAIDs" ]
[ 0, 0, 2, 0, 0, 2, 0, 2, 2, 2, 0, 2, 2, 0, 2, 2, 0, 0, 2, 2, 2, 0, 0, 1 ]
NCT01582191
14:34:chronic_disease,66:88:chronic_disease,90:109:chronic_disease,120:132:treatment,143:162:treatment
Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support
3
[ "Uncontrolled", "intercurrent", "illness", "including", ",", "but", "not", "limited", "to", ",", "uncontrolled", "infection", ",", "uncontrolled", "asthma", ",", "need", "for", "hemodialysis", ",", "need", "for", "ventilatory", "support" ]
[ 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 1 ]
NCT01581580
1:11:treatment,66:90:chronic_disease,92:97:cancer,102:108:chronic_disease,132:149:chronic_disease
MR-imaging with evidence indicative of secondary disease such as iron deposits in putamen, tumor, or stroke, which could cause the movement disorder
3
[ "MR-imaging", "with", "evidence", "indicative", "of", "secondary", "disease", "such", "as", "iron", "deposits", "in", "putamen", ",", "tumor", ",", "or", "stroke", ",", "which", "could", "cause", "the", "movement", "disorder" ]
[ 1, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 2, 2, 0, 3, 0, 0, 2, 0, 0, 0, 0, 0, 2, 2 ]
NCT01573429
1:15:treatment,17:30:treatment,32:41:treatment,43:51:treatment,53:67:treatment,69:79:treatment,81:105:treatment,107:120:treatment,122:132:treatment,134:147:treatment,149:160:treatment,165:177:treatment
Salicylic acid, acetaminophen, ibuprofen, naproxen, mefenamic acid, diclofenac, gliclazide carbamazepine, valproic acid, cimetidine, sulfasalazine, amoxicillin and erythromycin
3
[ "Salicylic", "acid", ",", "acetaminophen", ",", "ibuprofen", ",", "naproxen", ",", "mefenamic", "acid", ",", "diclofenac", ",", "gliclazide", "carbamazepine", ",", "valproic", "acid", ",", "cimetidine", ",", "sulfasalazine", ",", "amoxicillin", "and", "erythromycin" ]
[ 1, 1, 0, 1, 0, 1, 0, 1, 0, 1, 1, 0, 1, 0, 1, 1, 0, 1, 1, 0, 1, 0, 1, 0, 1, 0, 1 ]
NCT01572480
102:113:treatment,117:129:treatment,160:170:treatment,174:185:treatment,233:243:allergy_name,254:266:allergy_name
History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or lenalidomide agents used in study, such as bortezomib or thalidomide, in addition to patients with known allergy to sulfobutyl ether <=- cyclodextrin (Captisol )
3
[ "History", "of", "allergic", "reactions", "attributed", "to", "compounds", "of", "similar", "chemical", "or", "biologic", "composition", "to", "carfilzomib", "or", "lenalidomide", "agents", "used", "in", "study", ",", "such", "as", "bortezomib", "or", "thalidomide", ",", "in", "addition", "to", "patients", "with", "known", "allergy", "to", "sulfobutyl", "ether", "<", "=-", "cyclodextrin", "(", "Captisol", ")" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 4, 0, 0, 0 ]
NCT01568918
24:44:treatment,46:58:treatment,60:72:treatment,74:88:treatment,90:99:treatment,101:110:treatment,122:131:treatment,147:157:treatment
Patients taking strong inhibitors of CYP3A4 (ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir/ritonavir, lopinavir/ritonavir, and conivaptan)
3
[ "Patients", "taking", "strong", "inhibitors", "of", "CYP3A4", "(", "ketoconazole", ",", "itraconazole", ",", "clarithromycin", ",", "ritonavir", ",", "indinavir/ritonavir", ",", "lopinavir/ritonavir", ",", "and", "conivaptan", ")" ]
[ 0, 0, 0, 1, 1, 1, 0, 1, 0, 1, 0, 1, 0, 1, 0, 1, 0, 1, 0, 0, 1, 0 ]
NCT01562626
17:28:treatment,36:53:treatment,64:83:treatment
Currently using antibiotics and/or anti fungal agent (however, topical antibiotics are permitted)
3
[ "Currently", "using", "antibiotics", "and/or", "anti", "fungal", "agent", "(", "however", ",", "topical", "antibiotics", "are", "permitted", ")" ]
[ 0, 0, 1, 0, 1, 1, 1, 0, 0, 0, 1, 1, 0, 0, 0 ]
NCT01562626
44:54:chronic_disease,62:77:treatment,68:77:treatment,83:98:treatment,100:112:treatment,122:144:treatment
Patients who have not fully recovered from toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment)
3
[ "Patients", "who", "have", "not", "fully", "recovered", "from", "toxicities", "of", "any", "prior", "treatment", "with", "cytotoxic", "drugs", ",", "radiotherapy", "or", "other", "anti-cancer", "modalities", "(", "returned", "to", "baseline", "status", "as", "noted", "before", "most", "recent", "treatment", ")" ]
[ 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 1, 1, 0, 1, 1, 0, 1, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01562626
1:13:treatment,,38:47:treatment,53:60:treatment,62:84:treatment,,103:126:treatment,
radiotherapy within 4 weeks prior to treatment with APS001F (intensive radiotherapy within 6 weeks or palliative radiotherapy within 2 weeks)
3
[ "radiotherapy", "within", "4", "weeks", "prior", "to", "treatment", "with", "APS001F", "(", "intensive", "radiotherapy", "within", "6", "weeks", "or", "palliative", "radiotherapy", "within", "2", "weeks", ")" ]
[ 1, 0, 0, 0, 0, 0, 1, 0, 1, 0, 1, 1, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0 ]
NCT01555554
41:52:allergy_name,70:87:chronic_disease,93:118:treatment
They report sensitivity or allergies to propranolol, or a history of PTSD exacerbation with prior propranolol therapy
3
[ "They", "report", "sensitivity", "or", "allergies", "to", "propranolol", ",", "or", "a", "history", "of", "PTSD", "exacerbation", "with", "prior", "propranolol", "therapy" ]
[ 0, 0, 0, 0, 0, 0, 4, 0, 0, 0, 0, 0, 2, 2, 0, 1, 1, 1 ]
NCT01554371
22:30:treatment,43:55:chronic_disease,71:91:treatment
Patients must be off steroids with no new CNS symptoms or findings on radiographic imaging for 1 month
3
[ "Patients", "must", "be", "off", "steroids", "with", "no", "new", "CNS", "symptoms", "or", "findings", "on", "radiographic", "imaging", "for", "1", "month" ]
[ 0, 0, 0, 0, 1, 0, 0, 0, 2, 2, 0, 0, 0, 1, 1, 0, 0, 0 ]
NCT01553071
84:96:treatment,98:145:treatment,147:166:treatment,179:199:treatment,228:240:treatment,242:255:treatment,257:271:treatment,285:294:treatment,296:305:treatment,319:331:treatment,333:347:treatment,349:354:treatment,356:368:treatment,373:387:treatment,389:401:treatment,403:417:treatment,419:433:treatment,435:444:treatment,446:458:treatment,460:467:treatment,469:480:treatment,486:496:treatment
Concomitant use of the following drugs (see Concomitant Medications, Section 3.3): antioxidants; herbal or other alternative therapy medications; vitamin supplements (especially vitamins A, C, and E) other than a standard dose multivitamin, acetaminophen, cyclosporine A or analogue; verapamil; tamoxifen or analogue, ketoconazole, chlorpromazine; RU486; indomethacin; or sulfinpyrazone, tetracycline, nalidixic acid, nitrofurantoin, phenytoin, sulfonamides, lithium, ceftriaxone, and amiodarone
3
[ "Concomitant", "use", "of", "the", "following", "drugs", "(", "see", "Concomitant", "Medications", ",", "Section", "3.3", ")", ":", "antioxidants", ";", "herbal", "or", "other", "alternative", "therapy", "medications", ";", "vitamin", "supplements", "(", "especially", "vitamins", "A", ",", "C", ",", "and", "E", ")", "other", "than", "a", "standard", "dose", "multivitamin", ",", "acetaminophen", ",", "cyclosporine", "A", "or", "analogue", ";", "verapamil", ";", "tamoxifen", "or", "analogue", ",", "ketoconazole", ",", "chlorpromazine", ";", "RU486", ";", "indomethacin", ";", "or", "sulfinpyrazone", ",", "tetracycline", ",", "nalidixic", "acid", ",", "nitrofurantoin", ",", "phenytoin", ",", "sulfonamides", ",", "lithium", ",", "ceftriaxone", ",", "and", "amiodarone" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 1, 1, 1, 1, 1, 0, 1, 1, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 1, 1, 0, 0, 0, 1, 0, 1, 0, 0, 0, 1, 0, 1, 0, 1, 0, 1, 0, 0, 1, 0, 1, 0, 1, 1, 0, 1, 0, 1, 0, 1, 0, 1, 0, 1, 0, 0, 1 ]
NCT01553071
28:43:treatment,49:80:treatment,69:80:treatment
Patients who have received prior treatment with oral or intravenous fenretinide as a single agent are eligible, provided they did not experience severe toxicity related to fenretinide
3
[ "Patients", "who", "have", "received", "prior", "treatment", "with", "oral", "or", "intravenous", "fenretinide", "as", "a", "single", "agent", "are", "eligible", ",", "provided", "they", "did", "not", "experience", "severe", "toxicity", "related", "to", "fenretinide" ]
[ 0, 0, 0, 0, 1, 1, 0, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01553071
86:104:chronic_disease,106:142:chronic_disease,144:168:chronic_disease,170:188:chronic_disease,190:211:chronic_disease
Uncontrolled intercurrent illnesses including, but not limited to, ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, coagulation disorders
3
[ "Uncontrolled", "intercurrent", "illnesses", "including", ",", "but", "not", "limited", "to", ",", "ongoing", "or", "active", "systemic", "infection", ",", "symptomatic", "congestive", "heart", "failure", ",", "unstable", "angina", "pectoris", ",", "cardiac", "arrhythmia", ",", "coagulation", "disorders" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 0, 2, 2, 2, 2, 0, 2, 2, 2, 0, 2, 2, 0, 2, 2 ]
NCT01547429
84:92:chronic_disease,94:108:treatment,117:129:chronic_disease,131:146:chronic_disease,170:184:chronic_disease
Abnormality of the iris or ocular structure which would preclude fixation, such as aniridia, hemiiridectomy, severe iris atrophy, rubeosis iridis, or other compromising iris pathology
3
[ "Abnormality", "of", "the", "iris", "or", "ocular", "structure", "which", "would", "preclude", "fixation", ",", "such", "as", "aniridia", ",", "hemiiridectomy", ",", "severe", "iris", "atrophy", ",", "rubeosis", "iridis", ",", "or", "other", "compromising", "iris", "pathology" ]
[ 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 1, 0, 0, 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0 ]
NCT01543490
11:30:treatment,49:82:treatment,68:82:treatment,
Have used topical medications on the eyelids or topical ophthalmic corticosteroid medications or systemic use of a corticosteroid mediation within 14 days prior to dosing and/or plan to use them throughout the duration of the study
3
[ "Have", "used", "topical", "medications", "on", "the", "eyelids", "or", "topical", "ophthalmic", "corticosteroid", "medications", "or", "systemic", "use", "of", "a", "corticosteroid", "mediation", "within", "14", "days", "prior", "to", "dosing", "and/or", "plan", "to", "use", "them", "throughout", "the", "duration", "of", "the", "study" ]
[ 0, 0, 1, 1, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01538966
1:11:chronic_disease,24:43:treatment,66:69:treatment,74:85:treatment
Acromegaly patients on combination therapy with maximum doses of SRL and Pegvisomant (daily or weekly
3
[ "Acromegaly", "patients", "on", "combination", "therapy", "with", "maximum", "doses", "of", "SRL", "and", "Pegvisomant", "(", "daily", "or", "weekly" ]
[ 2, 0, 0, 1, 1, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0 ]
NCT01536522
23:34:chronic_disease,38:53:chronic_disease,133:156:chronic_disease,179:192:chronic_disease
Any other significant respiratory or cardiac disease or the presence of clinically important comorbidities, including, uncontrolled coronary artery disease, acute or and chronic renal failure
3
[ "Any", "other", "significant", "respiratory", "or", "cardiac", "disease", "or", "the", "presence", "of", "clinically", "important", "comorbidities", ",", "including", ",", "uncontrolled", "coronary", "artery", "disease", ",", "acute", "or", "and", "chronic", "renal", "failure" ]
[ 0, 0, 0, 2, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 2, 0, 0, 0, 0, 0, 2, 2 ]
NCT01532687
,14:27:treatment,29:38:treatment,61:72:chronic_disease,,
Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject
3
[ "Male", "partner", "sterilization", "(", "vasectomy", "with", "documentation", "of", "azoospermia", ")", "prior", "to", "the", "female", "subject", "'s", "entry", "into", "the", "study", ",", "and", "this", "male", "is", "the", "sole", "partner", "for", "that", "subject" ]
[ 0, 0, 1, 0, 1, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01532687
48:79:cancer,102:119:cancer,145:159:cancer
subjects with a history of completely resected non-melanomatous skin carcinoma, successfully treated in situ carcinoma, or successfully treated bladder cancer are eligible
3
[ "subjects", "with", "a", "history", "of", "completely", "resected", "non-melanomatous", "skin", "carcinoma", ",", "successfully", "treated", "in", "situ", "carcinoma", ",", "or", "successfully", "treated", "bladder", "cancer", "are", "eligible" ]
[ 0, 0, 0, 0, 0, 0, 0, 3, 3, 3, 0, 0, 0, 3, 3, 3, 0, 0, 0, 0, 3, 3, 0, 0 ]
NCT01522768
,25:42:cancer,77:84:chronic_disease,86:103:chronic_disease,109:124:cancer,,,197:207:treatment,
At least one measurable metastatic lesion according to RECIST 1.1 criteria. Ascites, pleural effusions, and bone metastases are not considered measurable. Minimum indicator lesion size = 10 mm by helical CT or = 20 mm by conventional techniques. Pathological nodes must be = 15 mm by the short axis to be considered measurable
3
[ "At", "least", "one", "measurable", "metastatic", "lesion", "according", "to", "RECIST", "1.1", "criteria", ".", "Ascites", ",", "pleural", "effusions", ",", "and", "bone", "metastases", "are", "not", "considered", "measurable", ".", "Minimum", "indicator", "lesion", "size", "=", "10", "mm", "by", "helical", "CT", "or", "=", "20", "mm", "by", "conventional", "techniques", ".", "Pathological", "nodes", "must", "be", "=", "15", "mm", "by", "the", "short", "axis", "to", "be", "considered", "measurable" ]
[ 0, 0, 0, 0, 3, 3, 0, 0, 0, 0, 0, 0, 2, 0, 2, 2, 0, 0, 3, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01522768
44:72:chronic_disease,81:106:chronic_disease,108:132:chronic_disease,,159:174:chronic_disease,196:206:chronic_disease,208:229:chronic_disease,
History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to study entry
3
[ "History", "or", "presence", "of", "clinically", "relevant", "cardiovascular", "abnormalities", "such", "as", "uncontrolled", "hypertension", ",", "congestive", "heart", "failure", "NYHA", "classification", "of", "3", ",", "unstable", "angina", "or", "poorly", "controlled", "arrhythmia", ".", "Myocardial", "infarction", "within", "6", "months", "prior", "to", "study", "entry" ]
[ 0, 0, 0, 0, 0, 0, 2, 2, 0, 0, 2, 2, 0, 2, 2, 2, 0, 0, 0, 0, 0, 2, 2, 0, 0, 0, 2, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0 ]
NCT01522768
30:39:treatment,43:53:treatment,57:75:treatment
Prior disease progression on docetaxel or paclitaxel in metastatic setting
3
[ "Prior", "disease", "progression", "on", "docetaxel", "or", "paclitaxel", "in", "metastatic", "setting" ]
[ 0, 0, 0, 0, 1, 0, 1, 0, 1, 1 ]
NCT01515527
1:30:treatment,20:30:treatment,93:96:cancer
Prior therapy with decitabine will be allowed unless the patient experienced progression to AML while being treated with decitabine
3
[ "Prior", "therapy", "with", "decitabine", "will", "be", "allowed", "unless", "the", "patient", "experienced", "progression", "to", "AML", "while", "being", "treated", "with", "decitabine" ]
[ 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0 ]
NCT01508390
18:37:cancer,50:55:cancer,59:80:cancer,
No history of an invasive malignancy (other than basal or squamous skin cancers) in the last 5 years
3
[ "No", "history", "of", "an", "invasive", "malignancy", "(", "other", "than", "basal", "or", "squamous", "skin", "cancers", ")", "in", "the", "last", "5", "years" ]
[ 0, 0, 0, 0, 3, 3, 0, 0, 0, 3, 0, 3, 3, 3, 0, 0, 0, 0, 0, 0 ]
NCT01505569
17:38:cancer,55:63:cancer,68:79:cancer
Confirmation of germ cell tumor (GCT) histology (both seminoma and nonseminoma)
3
[ "Confirmation", "of", "germ", "cell", "tumor", "(", "GCT", ")", "histology", "(", "both", "seminoma", "and", "nonseminoma", ")" ]
[ 0, 0, 3, 3, 3, 3, 0, 0, 0, 0, 0, 3, 0, 3, 0 ]
NCT01505569
17:27:cancer,31:52:cancer,,117:145:treatment
Other High Risk Metastatic or Relapsed Solid Tumors - to be approved by 2 or more pediatric hematology/oncology and bone marrow transplant (BMT) physicians
3
[ "Other", "High", "Risk", "Metastatic", "or", "Relapsed", "Solid", "Tumors", "-", "to", "be", "approved", "by", "2", "or", "more", "pediatric", "hematology/oncology", "and", "bone", "marrow", "transplant", "(", "BMT", ")", "physicians" ]
[ 0, 0, 0, 3, 0, 3, 3, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 0, 0, 0 ]
NCT01505569
47:56:treatment,58:80:treatment,84:97:treatment,111:124:treatment,
Timing: patients must be fully recovered from radiation, induction chemotherapy or surgery prior to receiving consolidation, with minimum elapsed time of 2 weeks
3
[ "Timing", ":", "patients", "must", "be", "fully", "recovered", "from", "radiation", ",", "induction", "chemotherapy", "or", "surgery", "prior", "to", "receiving", "consolidation", ",", "with", "minimum", "elapsed", "time", "of", "2", "weeks" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 1, 0, 1, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01505062
25:45:chronic_disease,130:137:treatment,228:236:chronic_disease,238:275:chronic_disease,290:297:chronic_disease,299:320:chronic_disease,322:350:chronic_disease
Presence of significant ocular abnormalities in the study eye that in the opinion of the investigator would preclude the planned surgery, effective safety follow-up, or interfere with the interpretation of study endpoints (eg, glaucoma, corneal or significant lens opacities, pre-existing uveitis, intraocular infection, choroidal neovascularization)
3
[ "Presence", "of", "significant", "ocular", "abnormalities", "in", "the", "study", "eye", "that", "in", "the", "opinion", "of", "the", "investigator", "would", "preclude", "the", "planned", "surgery", ",", "effective", "safety", "follow-up", ",", "or", "interfere", "with", "the", "interpretation", "of", "study", "endpoints", "(", "eg", ",", "glaucoma", ",", "corneal", "or", "significant", "lens", "opacities", ",", "pre-existing", "uveitis", ",", "intraocular", "infection", ",", "choroidal", "neovascularization", ")" ]
[ 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 2, 2, 2, 2, 2, 0, 0, 2, 0, 2, 2, 0, 2, 2, 0 ]
NCT01500551
1:20:chronic_disease,112:137:chronic_disease,143:163:chronic_disease
Systemic JIA (sJIA) with active systemic features other than active joints and elevated acute phase reactants, persistent oligoarthritis, and undifferentiated JIA
3
[ "Systemic", "JIA", "(", "sJIA", ")", "with", "active", "systemic", "features", "other", "than", "active", "joints", "and", "elevated", "acute", "phase", "reactants", ",", "persistent", "oligoarthritis", ",", "and", "undifferentiated", "JIA" ]
[ 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 0, 0, 2, 2 ]
NCT01495637
20:25:treatment,29:62:treatment,70:94:treatment,96:118:treatment,120:133:treatment,135:147:treatment
Patients receiving acute or chronic immunosuppressive therapy (e.g., systemic corticosteroids, calcineurin inhibitors, mycophenolate, azathioprine) at the time of injury
3
[ "Patients", "receiving", "acute", "or", "chronic", "immunosuppressive", "therapy", "(", "e.g.", ",", "systemic", "corticosteroids", ",", "calcineurin", "inhibitors", ",", "mycophenolate", ",", "azathioprine", ")", "at", "the", "time", "of", "injury" ]
[ 0, 0, 1, 0, 1, 1, 1, 0, 0, 0, 1, 1, 0, 1, 1, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0 ]
NCT01494662
19:63:treatment,75:84:treatment,86:99:treatment,101:114:treatment,116:128:treatment,130:143:treatment,145:158:treatment,163:172:treatment
Concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), including phenytoin, carbamazepine, oxcarbazepine, fosphenytoin, phenobarbital, pentobarbital, or primidone
3
[ "Concurrent", "use", "of", "enzyme-inducing", "antiepileptic", "drugs", "(", "EIAEDs", ")", ",", "including", "phenytoin", ",", "carbamazepine", ",", "oxcarbazepine", ",", "fosphenytoin", ",", "phenobarbital", ",", "pentobarbital", ",", "or", "primidone" ]
[ 0, 0, 0, 1, 1, 1, 1, 0, 0, 0, 0, 1, 0, 1, 0, 1, 0, 1, 0, 1, 0, 1, 0, 0, 1 ]
NCT01494662
60:71:chronic_disease,93:100:treatment,,,163:175:treatment
In cohort 2, eligible patients will include those who have CNS disease that is amenable for surgery (typically < 3 brain metastases and with planned resection by neurosurgery)
3
[ "In", "cohort", "2", ",", "eligible", "patients", "will", "include", "those", "who", "have", "CNS", "disease", "that", "is", "amenable", "for", "surgery", "(", "typically", "<", "3", "brain", "metastases", "and", "with", "planned", "resection", "by", "neurosurgery", ")" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0 ]
NCT01494662
32:66:treatment,87:99:treatment,101:113:treatment,118:134:treatment,162:171:treatment,177:192:treatment,197:206:treatment,227:237:cancer,285:294:treatment
Patients who are receiving any cancer-directed concurrent therapy, such as concurrent chemotherapy, radiotherapy, or hormonal therapy while on study. Concurrent treatment with bisphosphonates and denosumab is allowed for bony metastases but should be started before the first dose of neratinib
3
[ "Patients", "who", "are", "receiving", "any", "cancer-directed", "concurrent", "therapy", ",", "such", "as", "concurrent", "chemotherapy", ",", "radiotherapy", ",", "or", "hormonal", "therapy", "while", "on", "study", ".", "Concurrent", "treatment", "with", "bisphosphonates", "and", "denosumab", "is", "allowed", "for", "bony", "metastases", "but", "should", "be", "started", "before", "the", "first", "dose", "of", "neratinib" ]
[ 0, 0, 0, 0, 0, 1, 1, 1, 0, 0, 0, 0, 1, 0, 1, 0, 0, 1, 1, 0, 0, 0, 0, 0, 1, 0, 1, 0, 1, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1 ]
NCT01494662
58:76:cancer,113:123:cancer,144:160:treatment
Patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis by physical exam or radiologic study
3
[ "Patients", "without", "pathologic", "or", "cytologic", "confirmation", "of", "metastatic", "disease", "should", "have", "unequivocal", "evidence", "of", "metastasis", "by", "physical", "exam", "or", "radiologic", "study" ]
[ 0, 0, 0, 0, 0, 0, 0, 3, 3, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 1, 1 ]
NCT01474889
1:25:chronic_disease,27:43:chronic_disease,48:62:chronic_disease
Untreated hypothyroidism, Addisons disease, or Celiac disease
3
[ "Untreated", "hypothyroidism", ",", "Addisons", "disease", ",", "or", "Celiac", "disease" ]
[ 2, 2, 0, 2, 2, 0, 0, 2, 2 ]
NCT01464034
1:25:chronic_disease,,,,62:70:chronic_disease,142:163:chronic_disease,
Congestive heart failure (NYHA class III to IV), symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention or myocardial infarction in the previous six months prior to first dose
3
[ "Congestive", "heart", "failure", "(", "NYHA", "class", "III", "to", "IV", ")", ",", "symptomatic", "ischemia", ",", "conduction", "abnormalities", "uncontrolled", "by", "conventional", "intervention", "or", "myocardial", "infarction", "in", "the", "previous", "six", "months", "prior", "to", "first", "dose" ]
[ 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01464034
15:31:treatment,22:31:treatment,62:72:cancer,
Pts receiving active treatment or intervention for any other malignancy or pts who, at the Investigator's discretion, may require active treatment or intervention for any other malignancy within 8 months of starting study treatment
3
[ "Pts", "receiving", "active", "treatment", "or", "intervention", "for", "any", "other", "malignancy", "or", "pts", "who", ",", "at", "the", "Investigator", "'s", "discretion", ",", "may", "require", "active", "treatment", "or", "intervention", "for", "any", "other", "malignancy", "within", "8", "months", "of", "starting", "study", "treatment" ]
[ 0, 0, 1, 1, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01449149
35:53:cancer,80:82:treatment,86:89:treatment,119:128:treatment
Patients must have no evidence of metastatic disease based on routine imaging (CT or MRI of the chest/abdomen/pelvis, bone scan, etc.)
3
[ "Patients", "must", "have", "no", "evidence", "of", "metastatic", "disease", "based", "on", "routine", "imaging", "(", "CT", "or", "MRI", "of", "the", "chest/abdomen/pelvis", ",", "bone", "scan", ",", "etc", ".", ")" ]
[ 0, 0, 0, 0, 0, 0, 3, 3, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0 ]
NCT01445821
4:18:treatment,,,,100:122:chronic_disease,126:169:chronic_disease
On echocardiogram tricuspid annular peak systolic excursion (TAPSE) ≤ 1.8 cm or, grade II or worse Right Ventricular (RV) or Left Ventricular (LV) diastolic dysfunction
3
[ "On", "echocardiogram", "tricuspid", "annular", "peak", "systolic", "excursion", "(", "TAPSE", ")", "≤", "1.8", "cm", "or", ",", "grade", "II", "or", "worse", "Right", "Ventricular", "(", "RV", ")", "or", "Left", "Ventricular", "(", "LV", ")", "diastolic", "dysfunction" ]
[ 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 2, 0, 0, 0, 2, 2, 2, 2, 2, 0, 0 ]
NCT01438034
79:94:chronic_disease,96:107:chronic_disease,126:158:treatment
history or presence of underlying condition that could cause delayed puberty (chronic illness, weight loss, abnormal cranial magnetic resonance imaging (MRI))
3
[ "history", "or", "presence", "of", "underlying", "condition", "that", "could", "cause", "delayed", "puberty", "(", "chronic", "illness", ",", "weight", "loss", ",", "abnormal", "cranial", "magnetic", "resonance", "imaging", "(", "MRI", ")", ")" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 0, 2, 2, 0, 0, 0, 1, 1, 1, 1, 0, 0, 0 ]
NCT01434472
,30:48:treatment,56:74:treatment,76:91:treatment,93:116:treatment
< 5 half-lives for all other anti-cancer agents (e.g., targeted therapies, corticosteroids, immunomodulatory agents, etc.)
3
[ "<", "5", "half-lives", "for", "all", "other", "anti-cancer", "agents", "(", "e.g.", ",", "targeted", "therapies", ",", "corticosteroids", ",", "immunomodulatory", "agents", ",", "etc", ".", ")" ]
[ 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 1, 1, 0, 1, 0, 1, 1, 0, 0, 0, 0 ]
NCT01434472
49:58:treatment,,98:107:chronic_disease,118:152:chronic_disease
Patients must have an expected survival without treatment of > 60 days and must be free of major infection including human immunodeficiency virus (HIV)
3
[ "Patients", "must", "have", "an", "expected", "survival", "without", "treatment", "of", ">", "60", "days", "and", "must", "be", "free", "of", "major", "infection", "including", "human", "immunodeficiency", "virus", "(", "HIV", ")" ]
[ 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 0, 2, 2, 2, 2, 0, 0 ]
NCT01434316
,,53:60:treatment,65:74:treatment,79:104:treatment,263:272:treatment
Pregnant women are excluded from this study because ABT-888 and SCH727965 are anti-proliferative agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with ABT-888 and SCH727965, breastfeeding should be discontinued if the mother is treated with ABT-888 and SCH727965; these potential risks may also apply to other agents used in this study
3
[ "Pregnant", "women", "are", "excluded", "from", "this", "study", "because", "ABT-888", "and", "SCH727965", "are", "anti-proliferative", "agents", "with", "the", "potential", "for", "teratogenic", "or", "abortifacient", "effects", ";", "because", "there", "is", "an", "unknown", "but", "potential", "risk", "of", "adverse", "events", "in", "nursing", "infants", "secondary", "to", "treatment", "of", "the", "mother", "with", "ABT-888", "and", "SCH727965", ",", "breastfeeding", "should", "be", "discontinued", "if", "the", "mother", "is", "treated", "with", "ABT-888", "and", "SCH727965", ";", "these", "potential", "risks", "may", "also", "apply", "to", "other", "agents", "used", "in", "this", "study" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01434316
14:34:chronic_disease,76:92:chronic_disease,106:130:chronic_disease,132:156:chronic_disease,161:198:chronic_disease
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
3
[ "Uncontrolled", "intercurrent", "illness", "including", ",", "but", "not", "limited", "to", "ongoing", "or", "active", "infection", ",", "symptomatic", "congestive", "heart", "failure", ",", "unstable", "angina", "pectoris", ",", "or", "psychiatric", "illness/social", "situations", "that", "would", "limit", "compliance", "with", "study", "requirements" ]
[ 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 0, 0, 2, 2, 2, 0, 2, 2, 2, 0, 0, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0 ]
NCT01433965
23:35:cancer,,,,108:118:cancer,120:155:cancer,160:201:cancer
Disease free of other malignancies beside the AML or MDS for ≥ 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast
3
[ "Disease", "free", "of", "other", "malignancies", "beside", "the", "AML", "or", "MDS", "for", "≥", "2", "years", "with", "exception", "of", "currently", "treated", "basal", "cell", ",", "squamous", "cell", "carcinoma", "of", "the", "skin", ",", "or", "carcinoma", "in", "situ", "of", "the", "cervix", "or", "breast" ]
[ 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 3, 3, 0, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 0, 0, 0, 0, 0, 0 ]
NCT01430390
37:45:cancer,177:198:chronic_disease,220:242:chronic_disease,,262:271:treatment
Active central nervous system (CNS) leukemia, as defined by unequivocal morphologic evidence of lymphoblasts in the cerebrospinal fluid (CSF) or symptomatic CNS leukemia (i.e. cranial nerve palsies or other significant neurologic dysfunction) within 28 days of treatment
3
[ "Active", "central", "nervous", "system", "(", "CNS", ")", "leukemia", ",", "as", "defined", "by", "unequivocal", "morphologic", "evidence", "of", "lymphoblasts", "in", "the", "cerebrospinal", "fluid", "(", "CSF", ")", "or", "symptomatic", "CNS", "leukemia", "(", "i.e", ".", "cranial", "nerve", "palsies", "or", "other", "significant", "neurologic", "dysfunction", ")", "within", "28", "days", "of", "treatment" ]
[ 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 2, 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 1 ]
NCT01430390
,,34:72:chronic_disease,74:86:chronic_disease,93:117:chronic_disease,124:140:chronic_disease,152:181:treatment,172:181:treatment,,198:208:treatment
Patients with active (grade 2-4) acute graft versus host disease (GVHD), chronic GVHD or an overt autoimmune disease (e.g. hemolytic anemia) requiring glucocorticosteroid treatment (>0.5 mg/kg/day prednisone or its equivalent) as treatment
3
[ "Patients", "with", "active", "(", "grade", "2-4", ")", "acute", "graft", "versus", "host", "disease", "(", "GVHD", ")", ",", "chronic", "GVHD", "or", "an", "overt", "autoimmune", "disease", "(", "e.g", ".", "hemolytic", "anemia", ")", "requiring", "glucocorticosteroid", "treatment", "(", ">", "0.5", "mg/kg/day", "prednisone", "or", "its", "equivalent", ")", "as", "treatment" ]
[ 0, 0, 0, 0, 0, 0, 0, 2, 2, 2, 2, 2, 2, 0, 0, 0, 2, 2, 0, 0, 2, 2, 2, 0, 0, 0, 2, 2, 0, 0, 1, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0 ]
NCT01430390
48:60:cancer,,109:132:treatment,134:143:treatment,145:157:treatment,165:179:treatment
Relapse on this protocol is detection of CD19+ malignancies in bone marrow ≥ 5% or extramedullary lesion by morphology cytogenetics, molecular, radiographic and/or flow cytometry
3
[ "Relapse", "on", "this", "protocol", "is", "detection", "of", "CD19+", "malignancies", "in", "bone", "marrow", "≥", "5", "%", "or", "extramedullary", "lesion", "by", "morphology", "cytogenetics", ",", "molecular", ",", "radiographic", "and/or", "flow", "cytometry" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 1, 0, 1, 0, 1, 1 ]
NCT01428089
24:31:chronic_disease,35:56:chronic_disease,83:107:chronic_disease,109:115:chronic_disease,139:163:treatment
Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure; asthma requiring intermittent systemic corticosteroids; etc.)
3
[ "Significant", "history", "of", "cardiac", "or", "pulmonary", "dysfunction", "(", "e.g.", ",", "known", "or", "suspected", "congestive", "heart", "failure", ";", "asthma", "requiring", "intermittent", "systemic", "corticosteroids", ";", "etc", ".", ")" ]
[ 0, 0, 0, 2, 0, 2, 2, 0, 0, 0, 0, 0, 0, 2, 2, 2, 0, 2, 0, 0, 1, 1, 0, 0, 0, 0 ]
NCT01422005
39:64:chronic_disease,66:74:chronic_disease,89:103:chronic_disease,105:117:chronic_disease,119:126:chronic_disease,130:147:chronic_disease
Complicating medical problems such as uncontrolled hypertension, diabetes with signs of polyneuropathy, severe renal, cardiac or pulmonary disease, or evidence of other concurrent neurologic or orthopedic conditions precluding the subject from complying with the study protocol
3
[ "Complicating", "medical", "problems", "such", "as", "uncontrolled", "hypertension", ",", "diabetes", "with", "signs", "of", "polyneuropathy", ",", "severe", "renal", ",", "cardiac", "or", "pulmonary", "disease", ",", "or", "evidence", "of", "other", "concurrent", "neurologic", "or", "orthopedic", "conditions", "precluding", "the", "subject", "from", "complying", "with", "the", "study", "protocol" ]
[ 0, 0, 0, 0, 0, 2, 2, 0, 2, 0, 0, 0, 2, 0, 2, 2, 0, 2, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01421810
,88:98:treatment,119:141:chronic_disease,,224:230:treatment,,,,,,,,
Screening labs within age-appropriate normal range, with the exception of a mildly low hematocrit (see below) and the hormonal abnormalities inherent in obesity which could include mildly elevated luteinizing hormone (LH), lipids, testosterone, prolactin, DHEAS, E2, glucose, and insulin; and decreased follicle-stimulating hormone (FSH) and/or sex hormone-binding globulin (SHBG)
3
[ "Screening", "labs", "within", "age-appropriate", "normal", "range", ",", "with", "the", "exception", "of", "a", "mildly", "low", "hematocrit", "(", "see", "below", ")", "and", "the", "hormonal", "abnormalities", "inherent", "in", "obesity", "which", "could", "include", "mildly", "elevated", "luteinizing", "hormone", "(", "LH", ")", ",", "lipids", ",", "testosterone", ",", "prolactin", ",", "DHEAS", ",", "E2", ",", "glucose", ",", "and", "insulin", ";", "and", "decreased", "follicle-stimulating", "hormone", "(", "FSH", ")", "and/or", "sex", "hormone-binding", "globulin", "(", "SHBG", ")" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01420887
45:65:chronic_disease,74:94:chronic_disease,96:125:chronic_disease,129:141:chronic_disease
Progressive or recurrent contracture due to inflammatory disease such as rheumatoid arthritis, juvenile idiopathic arthritis or chondrolysis
3
[ "Progressive", "or", "recurrent", "contracture", "due", "to", "inflammatory", "disease", "such", "as", "rheumatoid", "arthritis", ",", "juvenile", "idiopathic", "arthritis", "or", "chondrolysis" ]
[ 0, 0, 0, 0, 0, 0, 2, 2, 0, 0, 2, 2, 0, 2, 2, 2, 0, 2 ]
NCT01419561
1:7:chronic_disease,9:17:chronic_disease,19:33:chronic_disease,37:56:chronic_disease
Nausea, anorexia, abdominal pain or altered bowel habit
3
[ "Nausea", ",", "anorexia", ",", "abdominal", "pain", "or", "altered", "bowel", "habit" ]
[ 2, 0, 2, 0, 2, 2, 0, 2, 2, 2 ]
NCT01415882
7:36:chronic_disease,40:52:treatment,115:122:treatment
Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing
3
[ "Known", "gastrointestinal", "(", "GI", ")", "disease", "or", "GI", "procedure", "that", "could", "interfere", "with", "the", "oral", "absorption", "or", "tolerance", "of", "MLN9708", "including", "difficulty", "swallowing" ]
[ 0, 2, 2, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0 ]
NCT01415752
4:17:treatment,22:25:cancer,,46:61:treatment
No prior therapy for MCL, except < 1 week of steroid therapy for symptom control
3
[ "No", "prior", "therapy", "for", "MCL", ",", "except", "<", "1", "week", "of", "steroid", "therapy", "for", "symptom", "control" ]
[ 0, 1, 1, 0, 3, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0 ]
NCT01415752
60:85:chronic_disease,132:160:treatment,164:172:treatment,,,
Patients randomized to Arms G or H who have a history of a thrombotic vascular event will be required to have therapeutic doses of low-molecular weight heparin or warfarin to maintain an INR between 2.0 - 3.0
3
[ "Patients", "randomized", "to", "Arms", "G", "or", "H", "who", "have", "a", "history", "of", "a", "thrombotic", "vascular", "event", "will", "be", "required", "to", "have", "therapeutic", "doses", "of", "low-molecular", "weight", "heparin", "or", "warfarin", "to", "maintain", "an", "INR", "between", "2.0", "-", "3.0" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01407809
10:30:chronic_disease,,168:205:treatment,266:286:treatment,
Moderate visual function loss, defined as grade 3 on the Humphrey Visual Field Analyzer SITA Standard 24-2 Test grading scale (Table 4) at presentation and failure of treatment with acetazolamide (Diamox) given at efficient dose (2g/d or maximum tolerated dose) or Topiramate (Topamax) given at efficient dose (maximum 150mg daily)
3
[ "Moderate", "visual", "function", "loss", ",", "defined", "as", "grade", "3", "on", "the", "Humphrey", "Visual", "Field", "Analyzer", "SITA", "Standard", "24-2", "Test", "grading", "scale", "(", "Table", "4", ")", "at", "presentation", "and", "failure", "of", "treatment", "with", "acetazolamide", "(", "Diamox", ")", "given", "at", "efficient", "dose", "(", "2g/d", "or", "maximum", "tolerated", "dose", ")", "or", "Topiramate", "(", "Topamax", ")", "given", "at", "efficient", "dose", "(", "maximum", "150mg", "daily", ")" ]
[ 0, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01389024
1:30:chronic_disease,26:29:chronic_disease,45:52:treatment
Obstructive sleep apnea [OSA] and receiving therapy [e.g. continuous positive airway pressure], or being evaluated or followed by a specialist for management of severe OSA
3
[ "Obstructive", "sleep", "apnea", "[", "OSA", "]", "and", "receiving", "therapy", "[", "e.g", ".", "continuous", "positive", "airway", "pressure", "]", ",", "or", "being", "evaluated", "or", "followed", "by", "a", "specialist", "for", "management", "of", "severe", "OSA" ]
[ 2, 2, 2, 2, 2, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01389024
1:37:chronic_disease,46:58:chronic_disease,60:80:chronic_disease,82:103:chronic_disease,136:155:chronic_disease,
Upper or lower respiratory infection, active bronchospasm, acute chest syndrome, splenic sequestration or other acute complications of sickle cell disease other than pain in the last 4 weeks (from resolution of symptoms)
3
[ "Upper", "or", "lower", "respiratory", "infection", ",", "active", "bronchospasm", ",", "acute", "chest", "syndrome", ",", "splenic", "sequestration", "or", "other", "acute", "complications", "of", "sickle", "cell", "disease", "other", "than", "pain", "in", "the", "last", "4", "weeks", "(", "from", "resolution", "of", "symptoms", ")" ]
[ 2, 2, 2, 2, 2, 0, 0, 2, 0, 2, 2, 2, 0, 2, 2, 0, 0, 0, 0, 0, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01384513
86:104:treatment,108:110:treatment,232:246:treatment
Patients treated on this protocol will be without morphological evidence of disease (complete remission or CR), or if the patient has evidence of disease, the patient must have had at least a good partial response (PR) to the most recent therapy and the disease must be chemoresponsive
3
[ "Patients", "treated", "on", "this", "protocol", "will", "be", "without", "morphological", "evidence", "of", "disease", "(", "complete", "remission", "or", "CR", ")", ",", "or", "if", "the", "patient", "has", "evidence", "of", "disease", ",", "the", "patient", "must", "have", "had", "at", "least", "a", "good", "partial", "response", "(", "PR", ")", "to", "the", "most", "recent", "therapy", "and", "the", "disease", "must", "be", "chemoresponsive" ]
[ 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0 ]
NCT01379573
41:44:treatment,41:45:treatment,,,714:731:chronic_disease,,,,,
Mother may or may not already be taking HCQ. This latter point was discussed with Dr. Nathalie Costedoat-Chalumeau, who has published extensively on measurement of HCQ. While it might be optimal for the mothers anticipating enrollment in the study to all have been on HCQ prior to conception, this is impractical. Some may never achieve pregnancy and not want to take HCQ unless they conceive (especially those asymptomatic). On the other hand, women with SLE are likely to already be on HCQ and it would limit enrollment to exclude these patients if all must initiate HCQ only at enrollment in the first trimester. Although the accepted dogma is that HCQ requires several months for maximal efficacy in treating rheumatic disease, it is unknown whether this would apply to transplacental passage or fetal levels (which are impossible to measure). Dr. Costedoat-Chalumeau suggests that HCQ is probably a three compartment model which includes the circulation, tissues and cells. In the circulation, the half life is approximately 7 days and in the tissues, it is 40 days. In Dr. Costedoat-Chalumeau's experience, steady state blood levels of HCQ are achieved in 4-6 weeks. Thus, dosing the mother no later than 10 weeks gestation should provide sufficient fetal exposure before the vulnerable period of CHB which is generally accepted to span 18-24 wks. Furthermore, the placenta has to be formed for HCQ to gain access to the fetus and it may be effective quickly for the biology we are considering
3
[ "Mother", "may", "or", "may", "not", "already", "be", "taking", "HCQ", ".", "This", "latter", "point", "was", "discussed", "with", "Dr.", "Nathalie", "Costedoat-Chalumeau", ",", "who", "has", "published", "extensively", "on", "measurement", "of", "HCQ", ".", "While", "it", "might", "be", "optimal", "for", "the", "mothers", "anticipating", "enrollment", "in", "the", "study", "to", "all", "have", "been", "on", "HCQ", "prior", "to", "conception", ",", "this", "is", "impractical", ".", "Some", "may", "never", "achieve", "pregnancy", "and", "not", "want", "to", "take", "HCQ", "unless", "they", "conceive", "(", "especially", "those", "asymptomatic", ")", ".", "On", "the", "other", "hand", ",", "women", "with", "SLE", "are", "likely", "to", "already", "be", "on", "HCQ", "and", "it", "would", "limit", "enrollment", "to", "exclude", "these", "patients", "if", "all", "must", "initiate", "HCQ", "only", "at", "enrollment", "in", "the", "first", "trimester", ".", "Although", "the", "accepted", "dogma", "is", "that", "HCQ", "requires", "several", "months", "for", "maximal", "efficacy", "in", "treating", "rheumatic", "disease", ",", "it", "is", "unknown", "whether", "this", "would", "apply", "to", "transplacental", "passage", "or", "fetal", "levels", "(", "which", "are", "impossible", "to", "measure", ")", ".", "Dr.", "Costedoat-Chalumeau", "suggests", "that", "HCQ", "is", "probably", "a", "three", "compartment", "model", "which", "includes", "the", "circulation", ",", "tissues", "and", "cells", ".", "In", "the", "circulation", ",", "the", "half", "life", "is", "approximately", "7", "days", "and", "in", "the", "tissues", ",", "it", "is", "40", "days", ".", "In", "Dr.", "Costedoat-Chalumeau", "'s", "experience", ",", "steady", "state", "blood", "levels", "of", "HCQ", "are", "achieved", "in", "4-6", "weeks", ".", "Thus", ",", "dosing", "the", "mother", "no", "later", "than", "10", "weeks", "gestation", "should", "provide", "sufficient", "fetal", "exposure", "before", "the", "vulnerable", "period", "of", "CHB", "which", "is", "generally", "accepted", "to", "span", "18-24", "wks", ".", "Furthermore", ",", "the", "placenta", "has", "to", "be", "formed", "for", "HCQ", "to", "gain", "access", "to", "the", "fetus", "and", "it", "may", "be", "effective", "quickly", "for", "the", "biology", "we", "are", "considering" ]
[ 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1 ]
NCT01371630
,21:29:treatment,31:42:treatment,61:74:treatment,78:95:treatment
less than 1 week of steroids, vincristine, and/or 1 dose of anthracycline or alkylating agents
3
[ "less", "than", "1", "week", "of", "steroids", ",", "vincristine", ",", "and/or", "1", "dose", "of", "anthracycline", "or", "alkylating", "agents" ]
[ 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 1, 0, 1, 1 ]
NCT01366612
1:13:treatment,17:29:treatment,,59:68:treatment,105:117:treatment,119:129:treatment,131:142:treatment,144:161:treatment,163:172:treatment,174:197:treatment,202:213:treatment
Chemotherapy or radiotherapy within 14 days of initiating treatment in this study with the exception of lenalidomide, decitabine, azacitidine, imatinib mesylate, dasatinib, nilotinib hydrochloride and hydroxyurea
3
[ "Chemotherapy", "or", "radiotherapy", "within", "14", "days", "of", "initiating", "treatment", "in", "this", "study", "with", "the", "exception", "of", "lenalidomide", ",", "decitabine", ",", "azacitidine", ",", "imatinib", "mesylate", ",", "dasatinib", ",", "nilotinib", "hydrochloride", "and", "hydroxyurea" ]
[ 1, 0, 1, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 1, 0, 1, 1, 0, 1, 0, 1, 1, 0, 1 ]
NCT01366612
23:43:cancer,47:82:cancer,87:105:cancer,110:134:cancer,141:157:treatment
complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy
3
[ "complete", "resection", "of", "basal", "cell", "carcinoma", "or", "squamous", "cell", "carcinoma", "of", "the", "skin", ",", "an", "in", "situ", "malignancy", ",", "or", "low-risk", "prostate", "cancer", "after", "curative", "therapy" ]
[ 0, 0, 0, 3, 3, 3, 0, 3, 3, 3, 3, 3, 3, 0, 0, 3, 3, 3, 0, 0, 3, 3, 3, 0, 1, 1 ]
NCT01365169
20:43:chronic_disease,34:43:chronic_disease,57:63:cancer,108:127:chronic_disease
History of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder) (Arm 3 only)
3
[ "History", "of", "current", "oropharyngeal", "dysphagia", "unrelated", "to", "cancer", "diagnosis", "(", "e.g", ".", "dysphagia", "due", "to", "underlying", "neurogenic", "disorder", ")", "(", "Arm", "3", "only", ")" ]
[ 0, 0, 0, 2, 2, 0, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0 ]
NCT01360606
19:40:chronic_disease,25:40:chronic_disease,165:172:treatment,174:200:treatment,256:293:treatment
Patients can have extra-hepatic disease, provided the hepatic disease is the highest burden, the extra-hepatic disease is low burden and potentially treatable with surgery, ablative radiation therapy, or US Food and Drug Administration-approved first- or second-line systemic therapy regimens
3
[ "Patients", "can", "have", "extra-hepatic", "disease", ",", "provided", "the", "hepatic", "disease", "is", "the", "highest", "burden", ",", "the", "extra-hepatic", "disease", "is", "low", "burden", "and", "potentially", "treatable", "with", "surgery", ",", "ablative", "radiation", "therapy", ",", "or", "US", "Food", "and", "Drug", "Administration-approved", "first-", "or", "second-line", "systemic", "therapy", "regimens" ]
[ 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1 ]
NCT01356290
17:39:chronic_disease,66:73:treatment,79:100:chronic_disease
Any significant cardiovascular disease not controled by standard therapy e.g. systemic hypertension
3
[ "Any", "significant", "cardiovascular", "disease", "not", "controled", "by", "standard", "therapy", "e.g", ".", "systemic", "hypertension" ]
[ 0, 0, 2, 2, 0, 0, 0, 0, 1, 0, 0, 2, 2 ]
NCT01351103
1:19:treatment,66:73:cancer,84:125:treatment,118:125:treatment,170:189:chronic_disease,217:225:cancer,227:235:cancer,237:242:cancer,258:272:cancer,274:286:cancer,290:294:cancer,341:364:treatment
LGK974 with PDR001: Dose escalation: patients with the following cancers that were previously treated with anti-PD-1 therapy and whose best response on that therapy was progressive disease (i.e. primary refractory): melanoma, lung SCC, HNSCC. Patients with esophageal SCC, cervical SCC or TNBC who are either naïve or primary refractory to prior anti-PD-1 therapy
3
[ "LGK974", "with", "PDR001", ":", "Dose", "escalation", ":", "patients", "with", "the", "following", "cancers", "that", "were", "previously", "treated", "with", "anti-PD-1", "therapy", "and", "whose", "best", "response", "on", "that", "therapy", "was", "progressive", "disease", "(", "i.e", ".", "primary", "refractory", ")", ":", "melanoma", ",", "lung", "SCC", ",", "HNSCC", ".", "Patients", "with", "esophageal", "SCC", ",", "cervical", "SCC", "or", "TNBC", "who", "are", "either", "naïve", "or", "primary", "refractory", "to", "prior", "anti-PD-1", "therapy" ]
[ 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 3, 0, 0, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 3, 0, 3, 3, 0, 3, 0, 0, 0, 3, 3, 0, 3, 3, 0, 3, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1 ]
NCT01349101
19:25:cancer,27:36:cancer,41:48:cancer,,160:167:treatment,232:241:treatment
For patients with RAEB-1, RCMD+/-RS, or MDS NOS must have stable disease for 6 months (as documented by serial bone marrow examinations) in the absence of any therapy but growth factors or transfusion support. Patients who require treatment to control their disease must show chemo-responsiveness
3
[ "For", "patients", "with", "RAEB-1", ",", "RCMD+/-RS", ",", "or", "MDS", "NOS", "must", "have", "stable", "disease", "for", "6", "months", "(", "as", "documented", "by", "serial", "bone", "marrow", "examinations", ")", "in", "the", "absence", "of", "any", "therapy", "but", "growth", "factors", "or", "transfusion", "support", ".", "Patients", "who", "require", "treatment", "to", "control", "their", "disease", "must", "show", "chemo-responsiveness" ]
[ 0, 0, 0, 3, 0, 3, 0, 0, 3, 3, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0 ]
NCT01341080
3:27:treatment,,53:99:treatment,109:135:chronic_disease,147:168:chronic_disease,172:187:chronic_disease,243:255:chronic_disease,269:317:chronic_disease,319:346:chronic_disease,352:368:treatment,380:404:chronic_disease,,,
A cardiovascular procedure in the last 5 years (eg, percutaneous transluminal coronary angioplasty) or have cardiovascular instability (including myocardial infarction or unstable angina). Other cardiovascular exclusions include uncontrolled hypertension, significant neurological sequelae of cerebrovascular disease, peripheral vascular disease with prior amputation, or severe congestive heart failure (New York Heart Association class III or IV)
3
[ "A", "cardiovascular", "procedure", "in", "the", "last", "5", "years", "(", "eg", ",", "percutaneous", "transluminal", "coronary", "angioplasty", ")", "or", "have", "cardiovascular", "instability", "(", "including", "myocardial", "infarction", "or", "unstable", "angina", ")", ".", "Other", "cardiovascular", "exclusions", "include", "uncontrolled", "hypertension", ",", "significant", "neurological", "sequelae", "of", "cerebrovascular", "disease", ",", "peripheral", "vascular", "disease", "with", "prior", "amputation", ",", "or", "severe", "congestive", "heart", "failure", "(", "New", "York", "Heart", "Association", "class", "III", "or", "IV", ")" ]
[ 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 2, 2, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 2, 0, 0, 2, 2, 2, 2, 2, 0, 2, 2, 2, 0, 1, 1, 0, 0, 0, 2, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0 ]
NCT01333046
1:17:chronic_disease,29:47:chronic_disease,102:110:chronic_disease,118:121:chronic_disease,142:145:treatment
Active infection defined as infectious disease testing indicating that patient blood is reactive for Hep B, C and/or HIV and confirmed using PCR to measure viral load
3
[ "Active", "infection", "defined", "as", "infectious", "disease", "testing", "indicating", "that", "patient", "blood", "is", "reactive", "for", "Hep", "B", ",", "C", "and/or", "HIV", "and", "confirmed", "using", "PCR", "to", "measure", "viral", "load" ]
[ 2, 2, 0, 0, 2, 2, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 2, 0, 0, 2, 0, 0, 0, 1, 0, 0, 0, 0 ]
NCT01333046
6:14:cancer,20:37:cancer,72:75:cancer,90:108:treatment
with lymphoma as a second malignancy e.g. a Richters transformation of CLL after failing front line therapy
3
[ "with", "lymphoma", "as", "a", "second", "malignancy", "e.g", ".", "a", "Richters", "transformation", "of", "CLL", "after", "failing", "front", "line", "therapy" ]
[ 0, 3, 0, 0, 3, 3, 0, 0, 0, 0, 0, 0, 3, 0, 0, 1, 1, 1 ]
NCT01313533
18:60:treatment,66:95:treatment,,120:124:treatment
Participation in another interventional investigative study of a cardiovascular drug or device within 30 days prior to CABG
3
[ "Participation", "in", "another", "interventional", "investigative", "study", "of", "a", "cardiovascular", "drug", "or", "device", "within", "30", "days", "prior", "to", "CABG" ]
[ 0, 0, 1, 1, 1, 1, 0, 0, 1, 1, 1, 1, 0, 0, 0, 0, 0, 1 ]